← Back to screener

Eledon Pharmaceuticals, Inc. ELDN

Rank #1723 · Nasdaq · $0.2B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
43.6
P/E
-5.9
P/B
-4.41
ROE
74.6%
Op. Margin
–%
Debt Ratio
-122%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -5.9x, P/B -4.41x. Ranks in the top 95% of the universe.

Profitability ★★★★★
Excellent

ROE 74.6%. Ranks in the top 5% of the universe.

Safety ★★★★★
Excellent

Debt ratio -122%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014–$-0.0B$-0.0B$-0.0B–-7
2015$0.0B$-0.0B$-0.0B$-0.0B–-11
2016$0.0B$-0.0B$-0.0B$-0.1B–-11
2017–$-0.0B$-0.0B$0.0B–140
2018–$-0.0B$-0.0B$-0.0B–-53
2019–$-0.0B$-0.0B$0.0B–13
2020–$-0.0B$-0.0B$0.0B–10
2021–$-0.0B$-0.0B$0.0B–70
2022–$-0.0B$-0.0B$0.2B–3
2023–$-0.1B$-0.1B$0.2B–5
2024––$-0.1B$0.1B–97
2025––$-0.0B$-0.0B–-122

← See the full screener